Skip to main content

Advertisement

SpringerLink
Log in

Analyzing the impact of ATF3 in tumorigenesis and immune cell infiltration of ovarian tumor: a bioinformatics study

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

ATF3 is an essential transcription activator in regulating cancer-related genetic expression. To identify the role of ATF3 in ovarian tumor, we investigated the correlation between ATF3 expression and the clinicopathological properties using multiple database. The cBioPortal and GEPIA database displayed the clinical information of ovarian patients harboring or without harboring ATF3 mutation. Furthermore, we assessed the relationship between survival and ATF3 expression level using Kaplan–Meier plotter, which reveals that the ovarian patients with higher expression of ATF3 suffered the worse overall survival and progression-free survival. The differentially expressed genes were analyzed using gene ontology, protein–protein interaction network, and gene set enrichment analysis to identify the hub gene and critical pathways, significantly affecting the tumorigenesis of ovarian tumor. Finally, we assessed the correlation between ATF3 and immune cell infiltration using Tumor Immunoassay Resource (TIMER) database. The results demonstrated that higher expression has a positive correlation with macrophage infiltration, expression for M1- and M2-type macrophages. Our study suggests that ATF3 can regulate the cell cycle and heme-related oxidative phosphorylation process, and it may be a critical factor to regulate the macrophage cell to be infiltrated into ovarian cancer. ATF3 can be used as a biomarker for diagnosis and therapy of ovarian tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

References

  1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. The Lancet. 2014;384(9951):1376–88.

    Article  Google Scholar 

  2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96.

    Article  Google Scholar 

  3. Coffman LG, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich RJ. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res. 2016;175:92-102. e2.

    Article  Google Scholar 

  4. Patch A-M, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ. Whole–genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.

    Article  CAS  Google Scholar 

  5. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609.

    Article  Google Scholar 

  6. Madariaga A, Lheureux S, Oza AM. Tailoring ovarian cancer treatment: implications of BRCA1/2 mutations. Cancers. 2019;11(3):416.

    Article  CAS  Google Scholar 

  7. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5(5):355–66.

    Article  CAS  Google Scholar 

  8. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Investig. 2016;126(11):4157–73.

    Article  Google Scholar 

  9. Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685.

    Article  CAS  Google Scholar 

  10. Zhang R, Shi H, Ren F, Feng W, Cao Y, Li G, Liu Z, Ji P, Zhang M. MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways. J Exp Clin Cancer Res. 2019;38(1):1–13.

    Article  Google Scholar 

  11. Duncan RM, Reyes L, Moats K, Robinson RM, Murphy SA, Kaur B, Stessman HA, Dolloff NG. ATF3 coordinates antitumor synergy between epigenetic drugs and protein disulfide isomerase inhibitors. Can Res. 2020;80(16):3279–91.

    Article  CAS  Google Scholar 

  12. Chang YS, Jalgaonkar SP, Middleton JD, Hai T. Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis. Proc Natl Acad Sci. 2017;114(34):E7159-68.

    Article  CAS  Google Scholar 

  13. Yan C, Boyd DD. ATF3 regulates the stability of p53: a link to cancer. Cell Cycle (Georgetown, Tex). 2006;5(9):926–9.

    Article  CAS  Google Scholar 

  14. Lim R, Barker G, Liong S, Nguyen-Ngo C, Tong S, Kaitu’u-Lino Tu, Lappas M. ATF3 is a negative regulator of inflammation in human fetal membranes. Placenta. 2016;47:63–72.

    Article  CAS  Google Scholar 

  15. Zhang Z-B, Ruan C-C, Chen D-R, Zhang K, Yan C, Gao P-J. Activating transcription factor 3 SUMOylation is involved in angiotensin II-induced endothelial cell inflammation and dysfunction. J Mol Cell Cardiol. 2016;92:149–57.

    Article  CAS  Google Scholar 

  16. Chan CM, Macdonald CD, Litherland GJ, Wilkinson DJ, Skelton A, Europe-Finner GN, Rowan AD. Cytokine-induced MMP13 expression in human chondrocytes is dependent on activating transcription factor 3 (ATF3) regulation. J Biol Chem. 2017;292(5):1625–36.

    Article  CAS  Google Scholar 

  17. Lee S, Kim G-L, Kim NY, Kim S-J, Ghosh P, Rhee D-K. ATF3 stimulates IL-17A by regulating intracellular Ca2+/ROS-dependent IL-1β activation during Streptococcus pneumoniae infection. Front Immunol. 1954;2018:9.

    Google Scholar 

  18. Sood V, Sharma KB, Gupta V, Saha D, Dhapola P, Sharma M, Sen U, Kitajima S, Chowdhury S, Kalia M. ATF3 negatively regulates cellular antiviral signaling and autophagy in the absence of type I interferons. Sci Rep. 2017;7(1):1–17.

    Article  CAS  Google Scholar 

  19. Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies. Cancer Lett. 2019;458:123–35.

    Article  CAS  Google Scholar 

  20. Almeida FV, Douglass SM, Fane ME, Weeraratna AT. Bad company: microenvironmentally mediated resistance to targeted therapy in melanoma. Pigment Cell Melanoma Res. 2019;32(2):237–47.

    Article  Google Scholar 

  21. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity. 2018;49(1):178-193. e7.

    Article  CAS  Google Scholar 

  22. Hao M, Wu T, Chen Q, Lian X, Wu H. Hyperbranched polyglycerols as robust up-conversion nanoparticle coating layer for feasible cell imaging. Polymers. 2020;12(11):2592.

    Article  CAS  Google Scholar 

  23. Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. J Clin Invest. 2020;130(4):1752–66.

    Article  CAS  Google Scholar 

  24. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–45.

    Article  CAS  Google Scholar 

  25. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  Google Scholar 

  26. Brüggmann D, Pulch K, Klingelhöfer D, Pearce CL, Groneberg DA. Ovarian cancer: density equalizing mapping of the global research architecture. Int J Health Geogr. 2017;16(1):3.

    Article  Google Scholar 

  27. Lee KA, Hai TY, SivaRaman L, Thimmappaya B, Hurst HC, Jones NC, Green MR. A cellular protein, activating transcription factor, activates transcription of multiple E1A-inducible adenovirus early promoters. Proc Natl Acad Sci USA. 1987;84(23):8355–9.

    Article  CAS  Google Scholar 

  28. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.

    Article  Google Scholar 

  29. Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol. 2014;171(24):5507–23.

    Article  CAS  Google Scholar 

  30. Wu H, Chen Q, Jiao M, Xia X, Lian X, Huang N, Li K, Yin J, Shi B. Evaluation of nanomechanical properties of hyperbranched polyglycerols as prospective cell membrane engineering block. Colloids Surf B Biointerf. 2020;190:110968.

    Article  CAS  Google Scholar 

  31. Fiorito V, Chiabrando D, Petrillo S, Bertino F, Tolosano E. The multifaceted role of heme in cancer. Front Oncol. 2019;9:1540.

    Article  Google Scholar 

  32. Strainic MG, Pohlmann E, Valley CC, Sammeta A, Hussain W, Lidke DS, Medof ME. RTK signaling requires C3ar1/C5ar1 and IL-6R joint signaling to repress dominant PTEN, SOCS1/3 and PHLPP restraint. FASEB J. 2020;34(2):2105–25.

    Article  CAS  Google Scholar 

  33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  Google Scholar 

  34. Kaur A, Ecker BL, Douglass SM, Kugel CH, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 2019;9(1):64–81.

    Article  CAS  Google Scholar 

  35. Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333.

    Article  CAS  Google Scholar 

  36. Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019;9:421.

    Article  Google Scholar 

  37. Kobayashi M, Nakashima A, Yoshino O, Yoshie M, Ushijima A, Ito M, Ono Y, Shima T, Kawamura K, Ishizuka B, Saito S. Decreased effector regulatory T cells and increased activated CD4(+) T cells in premature ovarian insufficiency. Am J Reprod Immunol. 2019;81(6):e13125.

    Article  Google Scholar 

  38. Lan J, Sun L, Xu F, Liu L, Hu F, Song D, Hou Z, Wu W, Luo X, Wang J, Yuan X, Hu J, Wang G. M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer. Can Res. 2019;79(1):146–58.

    Article  CAS  Google Scholar 

  39. Zhao Q, Zhong J, Lu P, Feng X, Han Y, Ling C, Guo W, Zhou W. DOCK4 is a platinum-chemosensitive and prognostic-related biomarker in ovarian cancer. PPAR Res. 2021;2021:6629842.

    Article  Google Scholar 

Download references

Acknowledgements

This work is supported by Henan Province Medical Science and Technique Foundation (NO. LHGJ20200035).

Author information

Authors and Affiliations

  1. Department of Gynaecology, Henan Province People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, 450003, Henan, China

    Xiaoliu Li, Panpan Liu, Xiaona Sun, Runhong Ma, Ting Cui, Ting Wang, Yang Bai, Yuxia Li & Xianling Feng

  2. School of Life Sciences, Henan University, Kaifeng, 475000, Henan, China

    Xiujuan Wu

Authors
  1. Xiaoliu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panpan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaona Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Runhong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ting Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yang Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuxia Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiujuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xianling Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xiujuan Wu or Xianling Feng.

Ethics declarations

Conflict of interest

All the authors declared no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (CSV 65 kb)

Supplementary file2 (CSV 402 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Liu, P., Sun, X. et al. Analyzing the impact of ATF3 in tumorigenesis and immune cell infiltration of ovarian tumor: a bioinformatics study. Med Oncol 38, 91 (2021). https://doi.org/10.1007/s12032-021-01541-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-021-01541-7

Keywords

Search

Navigation